Clinical Trial Update: Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating AK-104, a PD-1/CTLA-4 bispecific antibody, in combination with chemotherapy as neoadjuvant treatment for advanced ovarian cancer; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• AK-104

Snippet

Sponsor: Anhui Provincial Hospital | Conditions: Advanced Ovarian Cancer, AK104(PD-1/CTLA-4 Bispecial Antibody) | Phase 3 | Status: NOT_YET_RECRUITING